BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 17556337)

  • 1. Studying the effects of new peritoneal dialysis solutions on the peritoneum.
    Chan TM; Yung S
    Perit Dial Int; 2007 Jun; 27 Suppl 2():S87-93. PubMed ID: 17556337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve?
    Chung SH; Stenvinkel P; Bergström J; Lindholm B
    Perit Dial Int; 2000; 20 Suppl 5():S57-67. PubMed ID: 11229614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biocompatible dialysis fluids for peritoneal dialysis.
    Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
    Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application of animal models to study the biocompatibility of bicarbonate-buffered peritoneal dialysis solutions.
    ter Wee PM; Beelen RH; van den Born J
    Kidney Int Suppl; 2003 Dec; (88):S75-83. PubMed ID: 14870880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biocompatibility of new peritoneal dialysis solutions: clinical experience.
    Garcia-Lopez E; Lindholm B; Tranaeus A
    Perit Dial Int; 2000; 20 Suppl 5():S48-56. PubMed ID: 11229612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New solutions for peritoneal dialysis in adult and pediatric patients.
    Shockley TR; Martis L; Tranaeus AP
    Perit Dial Int; 1999; 19 Suppl 2():S429-34. PubMed ID: 10406559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Icodextrin and Glucose Bicarbonate/Lactate-Buffered Peritoneal Dialysis Fluids on Effluent Cell Population and Biocompatibility Markers IL-6 and CA125 in Incident Peritoneal Dialysis Patients.
    Opatrná S; Pöpperlová A; Lysák D; Fuchsová R; Trefil L; Racek J; Topolčan O
    Ther Apher Dial; 2016 Apr; 20(2):149-57. PubMed ID: 26929256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
    Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
    BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in peritoneal dialysis solutions.
    Chen CJ; Moberly JB; Martis L
    Adv Perit Dial; 1998; 14():116-9. PubMed ID: 10649707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid.
    Skoufos L; Topley N; Cooker L; Dawnay A; Millar DJ; Holmes CJ; Faict D
    Kidney Int Suppl; 2003 Dec; (88):S94-9. PubMed ID: 14870882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.
    Opatrna S; Lysak D; Trefil L; Parker C; Topley N
    Perit Dial Int; 2012; 32(1):37-44. PubMed ID: 22302924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there such a thing as biocompatible peritoneal dialysis fluid?
    Schmitt CP; Aufricht C
    Pediatr Nephrol; 2017 Oct; 32(10):1835-1843. PubMed ID: 27722783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids.
    Ueda Y; Miyata T; Goffin E; Yoshino A; Inagi R; Ishibashi Y; Izuhara Y; Saito A; Kurokawa K; Van Ypersele De Strihou C
    Kidney Int; 2000 Dec; 58(6):2518-24. PubMed ID: 11115086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute effects of peritoneal dialysis solutions in the mesenteric microcirculation.
    Frajewicki V; Brod V; Kushnir D; Kohan R; Bitterman H
    Transl Res; 2009 May; 153(5):249-56. PubMed ID: 19375686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH.
    Zareie M; Keuning ED; ter Wee PM; Schalkwijk CG; Beelen RH; van den Born J
    Nephrol Dial Transplant; 2006 Jan; 21(1):208-16. PubMed ID: 16263741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic analysis of peritoneal fluid and solute transport with combination of glucose and icodextrin as osmotic agents.
    Galach M; Werynski A; Waniewski J; Freida P; Lindholm B
    Perit Dial Int; 2009; 29(1):72-80. PubMed ID: 19164256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of new peritoneal dialysis solutions in children.
    Canepa A; Verrina E; Perfumo F
    Kidney Int Suppl; 2008 Apr; (108):S137-44. PubMed ID: 18379537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritoneal dialysis solutions.
    Wang T; Lindholm B
    Perit Dial Int; 2001; 21 Suppl 3():S89-95. PubMed ID: 11887870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of new peritoneal dialysis solutions on leukocyte recruitment in the rat peritoneal membrane.
    Mortier S; Faict D; Gericke M; Lameire N; De Vriese A
    Nephron Exp Nephrol; 2005; 101(4):e139-45. PubMed ID: 16131808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasoactive components of dialysis solution.
    Zakaria el R; Patel AA; Li N; Matheson PJ; Garrison RN
    Perit Dial Int; 2008; 28(3):283-95. PubMed ID: 18474922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.